Pipeline · VNQ-512Active studySynthetic mock data
VNQ-512 — CLDN18.2
Antibody · Gastric · IND-enabling
Modality
Antibody
Target
CLDN18.2
Phase
IND-enabling
Toxicity flags
0
Mechanism
VNQ-512 is a antibody engineered to engage CLDN18.2 with the goal of a clinically meaningful response in Gastric. Currently in IND-enabling; next milestone: IND submission Q2.
Dose-escalation cohorts
Pre-clinical — no dose levels assigned yet.
Recent toxicity events
0 activeNo toxicity events for this candidate in the last 14 days.
Linked studies
No studies currently linked to this candidate.
Cross-links